-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Synaptogenix (SNPX) Vs. Its Competitors Financial Review
Synaptogenix (SNPX) Vs. Its Competitors Financial Review
Synaptogenix (NASDAQ:SNPX – Get Rating) is one of 962 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it contrast to its rivals? We will compare Synaptogenix to similar companies based on the strength of its earnings, risk, institutional ownership, analyst recommendations, valuation, dividends and profitability.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Synaptogenix and its rivals, as provided by MarketBeat.
Get Synaptogenix alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Synaptogenix | 0 | 0 | 1 | 0 | 3.00 |
Synaptogenix Competitors | 3141 | 13133 | 39362 | 635 | 2.67 |
Synaptogenix presently has a consensus target price of $14.00, indicating a potential upside of 108.96%. As a group, "Pharmaceutical preparations" companies have a potential upside of 106.03%. Given Synaptogenix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Synaptogenix is more favorable than its rivals.
Volatility and Risk
Synaptogenix has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Synaptogenix's rivals have a beta of 0.97, meaning that their average share price is 3% less volatile than the S&P 500.Valuation and Earnings
This table compares Synaptogenix and its rivals top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Synaptogenix | N/A | -$12.61 million | -3.19 |
Synaptogenix Competitors | $1.83 billion | $243.52 million | -4.11 |
Synaptogenix's rivals have higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
9.1% of Synaptogenix shares are owned by institutional investors. Comparatively, 42.0% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 1.9% of Synaptogenix shares are owned by company insiders. Comparatively, 15.1% of shares of all "Pharmaceutical preparations" companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Synaptogenix and its rivals' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Synaptogenix | N/A | -45.23% | -43.73% |
Synaptogenix Competitors | -3,202.84% | -160.99% | -24.58% |
Summary
Synaptogenix rivals beat Synaptogenix on 7 of the 13 factors compared.
Synaptogenix Company Profile
(Get Rating)
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
Synaptogenix (NASDAQ:SNPX – Get Rating) is one of 962 publicly-traded companies in the "Pharmaceutical preparations" industry, but how does it contrast to its rivals? We will compare Synaptogenix to similar companies based on the strength of its earnings, risk, institutional ownership, analyst recommendations, valuation, dividends and profitability.
Synaptogenix(納斯達克代碼:SNPX-GET Rating)是962家上市公司之一,但它與競爭對手有何不同?我們將根據Synaptogenix的收益、風險、機構所有權、分析師建議、估值、股息和盈利能力,將其與類似公司進行比較。
Analyst Recommendations
分析師建議
This is a breakdown of current ratings and target prices for Synaptogenix and its rivals, as provided by MarketBeat.
這是由MarketBeat提供的Synaptogenix及其競爭對手的當前評級和目標價格細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Synaptogenix | 0 | 0 | 1 | 0 | 3.00 |
Synaptogenix Competitors | 3141 | 13133 | 39362 | 635 | 2.67 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
突觸基因 | 0 | 0 | 1 | 0 | 3.00 |
Synaptogenix的競爭對手 | 3141 | 13133 | 39362 | 635 | 2.67 |
Synaptogenix presently has a consensus target price of $14.00, indicating a potential upside of 108.96%. As a group, "Pharmaceutical preparations" companies have a potential upside of 106.03%. Given Synaptogenix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Synaptogenix is more favorable than its rivals.
Synaptogenix目前的共識目標價為14.00美元,表明潛在上漲108.96%。作為一個整體,“藥物製劑”公司有106.03%的潛在上行空間。考慮到Synaptogenix更高的共識評級和更高的可能上行空間,股票研究分析師顯然認為Synaptogenix比它的競爭對手更有利。
Volatility and Risk
波動性和風險
Valuation and Earnings
估值和收益
This table compares Synaptogenix and its rivals top-line revenue, earnings per share (EPS) and valuation.
此表比較了Synaptogenix及其競爭對手的營收、每股收益(EPS)和估值。
Gross Revenue | Net Income | Price/Earnings Ratio | |
Synaptogenix | N/A | -$12.61 million | -3.19 |
Synaptogenix Competitors | $1.83 billion | $243.52 million | -4.11 |
總收入 | 淨收入 | 市盈率 | |
突觸基因 | 不適用 | -1,261萬元 | -3.19 |
Synaptogenix的競爭對手 | 18.3億美元 | 2.4352億美元 | -4.11 |
Synaptogenix's rivals have higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Synaptogenix的競爭對手比Synaptogenix的收入和收益更高。Synaptogenix的市盈率高於競爭對手,這表明它目前的價格高於同行業的其他公司。
Institutional and Insider Ownership
機構和內部人持股
9.1% of Synaptogenix shares are owned by institutional investors. Comparatively, 42.0% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 1.9% of Synaptogenix shares are owned by company insiders. Comparatively, 15.1% of shares of all "Pharmaceutical preparations" companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Synaptogenix 9.1%的股份由機構投資者持有。相比之下,所有“醫藥製劑”公司42.0%的股份由機構投資者持有。Synaptogenix 1.9%的股份由公司內部人士持有。相比之下,所有“醫藥製劑”公司15.1%的股份由公司內部人持有。強大的機構持股表明,對衝基金、大型基金管理公司和捐贈基金相信,一隻股票的長期表現將好於大盤。
Profitability
盈利能力
This table compares Synaptogenix and its rivals' net margins, return on equity and return on assets.
下表比較了Synaptogenix及其競爭對手的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Synaptogenix | N/A | -45.23% | -43.73% |
Synaptogenix Competitors | -3,202.84% | -160.99% | -24.58% |
淨利潤率 | 股本回報率 | 資產回報率 | |
突觸基因 | 不適用 | -45.23% | -43.73% |
Synaptogenix的競爭對手 | -3,202.84% | -160.99% | -24.58% |
Summary
摘要
Synaptogenix rivals beat Synaptogenix on 7 of the 13 factors compared.
在比較的13個因素中,Synaptogenix的競爭對手在7個方面擊敗了Synaptogenix。
Synaptogenix Company Profile
Synaptogenix公司簡介
(Get Rating)
(獲取評級)
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Synaptogenix公司是一家生物製藥公司,在臨牀前和臨牀開發方面有候選產品。它專注於開發一個基於一種名為Bryostatin-1的候選藥物的產品平臺,用於治療阿爾茨海默病。該公司還在評估bryostatin在其他神經退行性或認知疾病和功能障礙方面的治療應用,如脆性X綜合徵、多發性硬化症和Niemann-Pick C型疾病。Synaptogenix公司與斯坦福大學、西奈山伊坎醫學院以及利蘭·斯坦福初級大學董事會簽訂了許可協議。該公司成立於2012年,總部設在紐約。
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
接受Synaptogenix Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Synaptogenix和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧